What is Argos Therapeutics' stock symbol?
Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS."
Where is Argos Therapeutics' stock going? Where will Argos Therapeutics' stock price be in 2017?
7 equities research analysts have issued 12-month price objectives for Argos Therapeutics' shares. Their predictions range from $1.40 to $18.00. On average, they expect Argos Therapeutics' share price to reach $9.49 in the next twelve months.
When will Argos Therapeutics announce their earnings?
Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.
What are analysts saying about Argos Therapeutics stock?
Here are some recent quotes from research analysts about Argos Therapeutics stock:
FBR & Co analysts commented, "On the morning of February 22, Argos Therapeutics announced that the Independent Data Monitoring Committee (IDMC) recommended that the company’s pivotal Phase III ADAPT clinical trial of rocapuldencel-T (AGS-003) in combination with sunitinib (standard therapy) for the treatment of metastatic renal cell carcinoma (mRCC) be discontinued for futility based on its planned interim data analysis. The IDMC came to a conclusion that the study was unlikely to demonstrate a statistically significant improvement in overall survival (OS) in the combination treatment arm of rocapuldencel-T and sunitinib. The company is in the process of analyzing preliminary data from the trial, and its next steps involve discussing the data with the FDA." (2/23/2017)
- Needham & Company LLC analysts commented, "Argos announced that the pivotal Phase III ADAPT trial of rocapuldencel-T (AGS-003) in renal cell carcinoma (RCC) reached futility at a pre-specified interim analysis. The Independent Data Monitoring Committee (IDMC) has recommended discontinuation of the trial. Argos plans to leave the trial open pending further data review and FDA discussion, however, we view the likelihood of approval in RCC, our main valuation driver, as too uncertain. We are downgrading shares to Neutral." (2/22/2017)
According to Zacks Investment Research, "Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. " (2/7/2017)
Who owns Argos Therapeutics stock?
Argos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (0.43%), Wall Street Associates (0.20%) and Keybank National Association OH (0.06%). Company insiders that own Argos Therapeutics stock include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.
Who sold Argos Therapeutics stock? Who is selling Argos Therapeutics stock?
Argos Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates.
Who bought Argos Therapeutics stock? Who is buying Argos Therapeutics stock?
Argos Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp. Company insiders that have bought Argos Therapeutics stock in the last two years include Alexey Alexandrovic Vinogradov, Andrei Vladimirovich Petrov, Holle Philippe Marie Marce Van, International S Pharmstandard, Jean Lamarre, Jeffrey D Abbey and Joan Winterbottom.
How do I buy Argos Therapeutics stock?
Shares of Argos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Argos Therapeutics stock cost?
One share of Argos Therapeutics stock can currently be purchased for approximately $1.23.